← Back to Search

Cheetah® non-invasive cardiac monitoring system for Pre-eclampsia

N/A
Waitlist Available
Led By Maged Costantine, MD
Research Sponsored by Ohio State University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Able to speak English or Spanish
Preeclampsia with severe features, diagnosed using the American Congress of Obstetricians and Gynecologists (ACOG) standard criteria 4 requiring magnesium sulfate
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 hours postpartum
Awards & highlights

Study Summary

Use of Cheetah® Cardiac Monitoring System to Guide Discontinuation of Magnesium Sulfate in Women With Severe Preeclampsia

Eligible Conditions
  • Pre-eclampsia

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 hours postpartum
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 hours postpartum for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Duration of Magnesium Sulfate Use in the Postpartum Period Defined as the Duration in Hours Between Delivery and Discontinuation of Magnesium Sulfate.
Secondary outcome measures
Composite of Postpartum Adverse Outcomes
Evaluating Incidence of Need to Restart Magnesium Sulfate
Evaluating Number of Participants With Hospital Readmission for Preeclampsia
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Standard of careExperimental Treatment1 Intervention
24 hours of postpartum magnesium sulfate (current arbitrary standard of care)
Group II: Cheetah® non-invasive cardiac monitoring systemExperimental Treatment1 Intervention
Using the Cheetah® device to aid in an individualized duration of magnesium sulfate based on reduction in Systemic Vascular Resistance (SVR), up to a maximum of 24 hours postpartum.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cheetah® non-invasive cardiac monitoring system
2021
N/A
~60

Find a Location

Who is running the clinical trial?

Ohio State UniversityLead Sponsor
823 Previous Clinical Trials
501,150 Total Patients Enrolled
Maged Costantine, MDPrincipal Investigator - Ohio State University
Nationwide Children's Hospital
2 Previous Clinical Trials
1,598 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~13 spots leftby Mar 2025